Andrew Amiel

Andrew Amiel has a diverse work experience in the healthcare and life sciences industry. Andrew has held various roles in different companies, focusing on business development, investment, and strategy.

In 2008, Andrew started their career as an Analyst at Go4Venture, where they were involved in fundraising processes and financial analysis for clients. Andrew then interned at BNP Paribas in investment banking, conducting valuation analysis and market research.

From 2010 to 2012, Andrew worked as an Associate at Landmark Ventures, where they gained experience in the life sciences sector. Andrew then became a Life Sciences Sector Advisor at Go4Venture Advisers from 2014 to 2017, providing guidance in the industry.

In 2012, Andrew founded their own financial advisory firm called Lamiel Partners, specializing in healthcare and life sciences. Andrew focused on fundraising, M&A, business development, and market entry into the Chinese market.

Andrew has also been actively involved in the development of innovative medical technologies. Andrew served as an Investor and VP of Business Development and Strategy at LumiThera, Inc. since 2016, where they worked on the development and commercialization of a treatment for age-related macular degeneration.

In 2016, Andrew also became the Head of Business Development at Ammonett Pharma, where they played a key role in developing an oral growth hormone release hormone. During their time there, they successfully established the company's presence in orphan indications.

In 2020, Andrew joined CarThera as an Investor and Business Development professional, contributing to the development of a medical device that increases the permeability of blood vessels in the brain for targeted therapy.

Recently, Andrew has taken on the role of Vice President of Business Development at Endostart. Andrew is involved in the development and manufacture of medical devices for gastrointestinal endoscopy, utilizing the company's proprietary Magnetic Balloon Anchoring Technology.

Additionally, Andrew has investment experience in the healthcare sector as an Investor and EVP of Business Development and Investor Relations at Injectsense Inc. since 2015.

Throughout their career, Andrew has demonstrated a strong focus on business development, investment, and strategic planning in the healthcare and life sciences industry.

Andrew Amiel attended NYU Stern School of Business from 2005 to 2007, where they pursued a Co-Major in Finance and International Business and obtained a BA degree. There is no information available regarding their enrollment or completion of a degree at Babson College or their participation in the Investment Banking Institute.